Somatostatin Receptor Antagonist
- 1
-
NOTA-Octreotide
0 ImagesCat. No.: HY-P0036DCAS No.: 1427427-01-7NOTA‑Octreotide is a selective SSTR2‑targeting PET tracer. NOTA‑Octreotide binds specifically to SSTR2 and accumulates in SSTR2‑expressing tissues. NOTA‑Octreotide enables effective imaging of somatostatin receptor‑positive tumors in mice and shows high specific uptake in SSTR2‑expressing organs in healthy rats. NOTA-Octreotide can be used for PET imaging investigation of neuroendocrine tumors..
-
SSTR5 antagonist 1
0 ImagesSSTR5 antagonist 1 (compound 25a) is a selective and orally available somatostatin receptor subtype 5 (SSTR5) antagonist with IC50s of 9.6 and 57 nM for hSSTR5 and mSSTR5, respectively.
-
SRA880
0 ImagesSRA880 is a non-peptide and selective somatostatin sst(1) receptor antagonist. SRA880 exhibits antidepressant-like effects when in combination with Imipramine (HY-B1490A) .
-
SSTR5 antagonist 2 hydrochloride
0 ImagesSSTR5 antagonist 2 hydrochloride is a highly potent, oral active and selective somatostatin (receptor) subtype 5 (SSTR5) antagonist and has potential for the research of type 2 diabetes mellitus (T2DM).
-
SSTR5 antagonist 2
0 ImagesCat. No.: HY-114191CAS No.: 1254730-81-8SSTR5 antagonist 2 (compound 10) is a highly potent, oral active and selective somatostatin (receptor) subtype 5 (SSTR5) antagonist and has potential for the research of treat type 2 diabetes mellitus (T2DM).
-
SSTR5 antagonist 2 TFA
0 ImagesCat. No.: HY-114191ACAS No.: 1254733-98-6SSTR5 Antagonist 1 (compound 10) is a highly potent, oral active and selective somatostatin (receptor) subtype 5 (SSTR5) antagonist and has potential for the research of treat type 2 diabetes mellitus (T2DM).
-
SSTR5 antagonist 6
0 ImagesCat. No.: HY-160176CAS No.: 1007836-12-5SSTR5 antagonist 6 is an orally active somatostatin receptor subtype 5 (SSTR5) antagonist with an IC50 of 24 nM. SSTR5 antagonist 6 can be used in the study of type 2 diabetes.
-
SST1 receptor antagonist-1
0 ImagesCat. No.: HY-177278CAS No.: 868057-23-2SST1 receptor antagonist-1 (Compound 23) is a selective Somatostatin receptor 1 (SST1) antagonist with pKds of 9.11 and 8.79 for rSST1 and hSST1, respectively. SST1 receptor antagonist-1 can be used for retinal and endocrine dysfunctions, cancer and neuropsychiatric disorders research.
-
MK-1421
0 ImagesCat. No.: HY-12819CAS No.: 1235995-16-0MK-1421 is a potent and selective sstr3 antagonist. MK-1421 regulates insulin secretion by binding to the sstr3. MK-1421 can be used in the research of type 2 diabetes.
-
SST1 receptor antagonist-2
0 ImagesCat. No.: HY-177282CAS No.: 524743-70-2SST1 receptor antagonist-2 (Example 2) is a piperazine derivative and a somatostatin receptor 1 (SST1) antagonist. SST1 receptor antagonist-2 can be used in the research of psychiatric diseases, neurodegenerative diseases, tumors, as well as vascular disorders and immunological diseases.
-
SSTR5 antagonist 3
0 ImagesCat. No.: HY-157303CAS No.: 2851454-42-5SSTR5 antagonist 3 (Compound 23) is an orally active somatostatin receptor subtype 5 (SSTR5) antagonist with low hERG inhibition. SSTR5 antagonist 3 exhibits potency with IC50 values of 2.8 nM and 1.4 nM in human and mouse, respectively. SSTR5 antagonist 3 can be used for the research of anti-gallstone.
-
SSTR5 antagonist 1 (Standard)
0 ImagesCat. No.: HY-102037RCAS No.: 1628741-91-2SSTR5 antagonist 1 (Standard) is the analytical standard of SSTR5 antagonist 1 (HY-102037). This product is intended for research and analytical applications. SSTR5 antagonist 1 (compound 25a) is a selective and orally available somatostatin receptor subtype 5 (SSTR5) antagonist with IC50s of 9.6 and 57 nM for hSSTR5 and mSSTR5, respectively.
- 1
